{
    "clinical_study": {
        "@rank": "50131", 
        "arm_group": [
            {
                "arm_group_label": "RFA-125I group", 
                "arm_group_type": "Experimental", 
                "description": "The combination RFA and 125I (RFA-125I) (n = 68; 42 men, 26 women; mean age, 50.7 years; age range, 29-73 years) In this group, patients were accepted not only radiofrequency ablation (RFA) but also iodine-125."
            }, 
            {
                "arm_group_label": "RFA-only group", 
                "arm_group_type": "Active Comparator", 
                "description": "(n = 68; 47 men, 21 women; mean age, 48.9 years; age range, 30-74 years) In tis group,the patient were just peformed radiofrequency ablation alnoe."
            }
        ], 
        "brief_summary": {
            "textblock": "To prospectively evaluate whether use of combined radiofrequency ablation (RFA) and\n      percutaneous iodine-125 (125I) seeds implantation results in better survival compared with\n      use of RFA alone in patients with hepatocellular carcinoma."
        }, 
        "brief_title": "Hepatocellular Carcinoma Treated With Iodine-125 Implantation", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Liver Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study was local ethical committee approved; all patients gave written informed consent.\n      A total of 136 patients were randomly assigned to undergo RFA-125I (n = 68; 42 men, 26\n      women; mean age, 50.7 years; age range, 29-73 years) or RFA alone (n = 68; 47 men, 21 women;\n      mean age, 48.9 years; age range, 30-74 years). Patients with viable tumors at computed\n      tomography (CT) 4 weeks after treatment received additional treatment. Rates of local tumor\n      progression and overall survival were evaluated by using Kaplan-Meier and log-rank tests,\n      respectively. The relative prognostic significance of variables in predicting overall\n      survival and the time to tumor recurrence or metastasis were assessed with multivariate Cox\n      proportional hazards regression and logistic regression analyses, respectively."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        (a) age 18-75 years and refusal to undergo surgery; (b) a solitary HCC 7.0 cm in diameter\n        or smaller or multiple (up to three) HCCs 3.0 cm in diameter or smaller; (c) lesions\n        visible at ultrasonography (US), with an acceptable and safe path between the lesion and\n        the skin seen on the US scan; (d) no extrahepatic metastasis; (e) no imaging evidence of\n        tumor invasion into the major portal or hepatic vein branches; (f) no history of\n        encephalopathy, ascites refractory to diuretics, or variceal bleeding; (g) a platelet\n        count of more than 40 000 cells/mm3 and (h) no previous treatment for HCC except liver\n        resection.\n\n        Exclusion Criteria:\n\n        Exclusion criteria included active thyroid disease, serious concurrent medical illnesses,\n        extrahepatic diseases,  previous anticancer treatment before surgery, histologically\n        proved non-HCC tumors and women who were pregnant or breastfeeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "136", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01717729", 
            "org_study_id": "ABT-2000-235"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "RFA-125I group", 
                    "RFA-only group"
                ], 
                "description": "For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, Calif) and a needle electrode with a 15-gauge insulated cannula that had 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; Radio Therapeutics).The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi)", 
                "intervention_name": "Radiofrequency Ablation", 
                "intervention_type": "Procedure", 
                "other_name": "Radio Therapeutics, Mountain View, Calif"
            }, 
            {
                "arm_group_label": "RFA-125I group", 
                "description": "The 125I seeds (0.8 mm in diameter and 4.5mm in length) were enclosed in a NiTinol capsule (China Institute of Atomic Energy, Beijing). These seeds could produce 27.4-31.5 keV X-ray and 35.5 Kev \u03b3 ray, with a half-life of 59.6 days. The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi).", 
                "intervention_name": "iodine", 
                "intervention_type": "Radiation", 
                "other_name": "iodine-125 seed"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Iodine", 
                "Cadexomer iodine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "HCC, RFA, Iodine-125, Recurrence", 
        "lastchanged_date": "October 26, 2012", 
        "number_of_arms": "2", 
        "official_title": "Hepatocellular Carcinoma Treated With Radiofrequency Ablation With or Without Iodine-125 Implantation: A Prospective Study", 
        "overall_official": {
            "affiliation": "The second people's hospital", 
            "last_name": "kai yun chen, phD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint was the time to recurrence(TTR) was measured from the date of treatment to the time when the recurrent tumor was first diagnosed. At spiral CT after treatment, residual viable tumor tissue was considered to be present if enhancing areas were seen within the tumor on either arterial phase or portal venous phase images. Depending on the initial random treatment assignment, RFA-125I or RFA alone was repeated. Magnetic resonance (MR) imaging was performed if there was uncertainty at CT as to whether residual viable tumor tissue was present.", 
            "measure": "recurrence rate", 
            "safety_issue": "Yes", 
            "time_frame": "up to 6 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01717729"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The Second People's Hospital of GuangDong Province", 
            "investigator_full_name": "KaiYun Chen", 
            "investigator_title": "SURGERY", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "urvival time was defined as the interval between the first treatment and either death or last follow-up visit.", 
                "measure": "One-, 2-, 3-, 4-, and 5-year overall survival rates", 
                "safety_issue": "Yes", 
                "time_frame": "up to 6 years"
            }, 
            {
                "description": "At spiral CT 4 weeks after treatment, residual viable tumor tissue was considered to be present if enhancing areas were seen within the tumor on either arterial phase or portal venous phase images.", 
                "measure": "Complete Ablation", 
                "safety_issue": "Yes", 
                "time_frame": "up to 6 years"
            }
        ], 
        "source": "The Second People's Hospital of GuangDong Province", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Second People's Hospital of GuangDong Province", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2000", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}